Managing CAR T-Cell Therapy Toxicity

Advances in Managing CAR T-Cell Therapy Side EffectsПодробнее

Advances in Managing CAR T-Cell Therapy Side Effects

Thrive | Advice for Managing Potential CAR T-Cell Therapy Side EffectsПодробнее

Thrive | Advice for Managing Potential CAR T-Cell Therapy Side Effects

Understanding Possible Side Effects of CAR T-Cell TherapyПодробнее

Understanding Possible Side Effects of CAR T-Cell Therapy

TECVAYLI (Teclistamab) Everything You Need to KnowПодробнее

TECVAYLI (Teclistamab) Everything You Need to Know

Managing hematologic toxicity associated with CAR-T therapy & insights into the CAR-HEMATOTOX scoreПодробнее

Managing hematologic toxicity associated with CAR-T therapy & insights into the CAR-HEMATOTOX score

Addressing toxicity management after CAR-T therapy: an ongoing project of the EBMT & EHAПодробнее

Addressing toxicity management after CAR-T therapy: an ongoing project of the EBMT & EHA

Managing and treating CRS, neurological toxicity and cytopenias associated with CAR-T therapyПодробнее

Managing and treating CRS, neurological toxicity and cytopenias associated with CAR-T therapy

Management of CAR-T Toxicities: CRS, Neurological, Cytopenias, InfectionПодробнее

Management of CAR-T Toxicities: CRS, Neurological, Cytopenias, Infection

Management of Immuno-Toxicity in Patients Receiving CAR T-Cell Therapy– Dr.ClaireRoddie(May26-27'23)Подробнее

Management of Immuno-Toxicity in Patients Receiving CAR T-Cell Therapy– Dr.ClaireRoddie(May26-27'23)

The importance of managing hematologic toxicity associated with CAR-T therapyПодробнее

The importance of managing hematologic toxicity associated with CAR-T therapy

Acute lymphoblastic leukemia (ALL): Treatment options managing side effects and research advancesПодробнее

Acute lymphoblastic leukemia (ALL): Treatment options managing side effects and research advances

Managing CRS and neurotoxicities associated with CAR-T in ZUMA-3Подробнее

Managing CRS and neurotoxicities associated with CAR-T in ZUMA-3

Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapyПодробнее

Managing CAR-T therapy-related AEs & treatment options for patients who progress after CAR-T therapy

CAR T-cell Therapy: The Good, The Bad and The Long-Term 2022Подробнее

CAR T-cell Therapy: The Good, The Bad and The Long-Term 2022

Incidence & management of HLH-like toxicities after CD19 CAR-T therapyПодробнее

Incidence & management of HLH-like toxicities after CD19 CAR-T therapy

Impact of corticosteroids, tocilizumab or filgrastim on the outcomes of CAR-T therapy recipientsПодробнее

Impact of corticosteroids, tocilizumab or filgrastim on the outcomes of CAR-T therapy recipients

CAR-T Toxicities: CRS and ICANSПодробнее

CAR-T Toxicities: CRS and ICANS

Symptom Management in Multiple Myeloma | Dana-Farber Cancer InstituteПодробнее

Symptom Management in Multiple Myeloma | Dana-Farber Cancer Institute

What is ICANS?Подробнее

What is ICANS?

Managing toxicity post-CAR-T therapy in multiple myelomaПодробнее

Managing toxicity post-CAR-T therapy in multiple myeloma